MW Secret Files/Medical Miscellany.Pdf
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Level Diagnosis of Cervical Compressive Myelopathy: Signs, Symptoms, and Lesions Levels
Elmer Press Original Article J Neurol Res • 2013;3(5):135-141 Level Diagnosis of Cervical Compressive Myelopathy: Signs, Symptoms, and Lesions Levels Naoki Kasahata ficult to accurately localize the lesion before radiographic Abstract diagnosis. However, neurological level diagnosis of spinal cord is important for accurate lesion-specific level diagnosis, Background: To elucidate signs and symptoms corresponding to patients’ treatment, avoiding diagnostic error, differential di- each vertebral level for level-specific diagnoses. agnosis, and especially for accurate level diagnosis of other nonsurgical myelopathies. Moreover, level diagnosis should Methods: We studied 106 patients with cervical compressive my- be considered from multiple viewpoints. Therefore, we in- elopathy. Patients who showed a single compressive site on mag- tend to make level diagnosis of myelopathy more accurate. netic resonance imaging (MRI) were selected, and signs, symp- Previously, lesion-specific level diagnoses by determin- toms, and the levels of the MRI lesions were studied. ing a sensory disturbance area or location of numbness in Results: Five of 12 patients (41.7%) with C4-5 intervertebral level the hands had the highest accuracy [1, 2]. Previous stud- lesions showed decreased or absent biceps and brachioradialis re- ies reported that C3-4 intervertebral level lesions showed flexes, while 4 of these patients (33.3%) showed generalized hyper- increased or decreased biceps reflexes, deltoid weakness, reflexia. In comparison, 5 of 24 patients (20.8%) with C5-6 inter- and sensory disturbance of arms or forearms [1, 3, 4], while vertebral level lesions showed decreased or absent triceps reflexes; C4-5 intervertebral level lesions showed decreased biceps however, 9 of these patients (37.5%) showed decreased or absent reflexes, biceps weakness, and sensory disturbance of hands biceps and brachioradialis reflexes. -
Clinical Assessment
ID Canadian Study of Health and Aging - 3 CLINICAL ASSESSMENT CONSENSUS DIAGNOSTIC OPINION English: 1 To reach 'Part 1 - Final Diagnosis' the following are reviewed: Screening Questionnaire Informant or Caregiver Interview Clinical Assessment, Section 1: Clinician's Evaluation Clinical Assessment, Section 2: Clinician's Preliminary Diagnostic Opinion Neuropsychological Assessment, including Score Sheets and Evaluation Complete 1 Incomplete 2 YES NO Edited 1 2 Editor's # www.csha.ca C-i CONSENSUS DIAGNOSTIC OPINION ID Date of consensus conference / / dd mm yyyy NOTE: Circle only one of the diagnostic categories A to F. Fill in more detail where appropriate. Diagnoses must be made. Confidence in the diagnoses can be recorded for each diagnosis. PART 1 FINAL DIAGNOSIS 1 A. No cognitive impairment B1. Cognitive impairment but no dementia (CIND) (circle one or more of the subcategories below) 1 delirium 6 age-associated memory impairment 15 epilepsy 2 chronic alcohol abuse 7 mental retardation 16 socio-cultural 3 chronic drug intoxication 10 cerebral vascular, stroke 17 social isolation 4 depression 11 general vascular 18 blind/deaf 5 psychiatric disease 12 Parkinson's disease 19 unknown (other than depression) 13 brain tumour 8 other, specify: 14 multiple sclerosis B2. Specify most important of those listed in B.1 C. Alzheimer's Disease (circle only one of 1 or 2): 1 probable 2 possible (circle only one of 2.1 to 2.4): 2.1 atypical presentation/course (e.g. major aphasia, apraxia) specify: 2.2 with vascular components 2.3 with Parkinsonism (EP signs) 2.4 with coexisting disease D. Vascular dementia [ischemic score ] (circle only one of 1 to 4) 1 of acute onset 2 multiple cortical infarct 3 subcortical 4 mixed cortical and subcortical E. -
MW S Rationales Files/Brain Rationale.Pdf
A RATIONALE FOR THE BRAIN A RATIONALE FOR the BRAIN Assoc. Prof. Warwick Carter MB.BS; FRACGP; FAMA A guide to the diagnosis of diseases that may cause neurological symptoms. 1 A RATIONALE FOR THE BRAIN CONTENTS Introduction SECTION ONE Headache Diagnostic Chart A chart that leads the user through the headache symptoms to possible diagnoses. SECTION TWO Diagnostic Algorithm for Neurological Symptoms Symptoms involving the brain and the conditions that may be responsible SECTION THREE Neurological Conditions The symptoms, signs, investigation and treatment of medical conditions that may cause neurological symptoms. Appendices Mini-Mental Test Glasgow Coma Scale 2 A RATIONALE FOR THE BRAIN INTRODUCTION This book is designed for both the medical student and the doctor who is not a specialist in neurology. It will take the user through a logical rationale in order to diagnose, and then treat, virtually every neurological condition likely to be encountered outside a specialist practice. There are two ways to reach a diagnosis, using the chart in Section One, or the Diagnostic Algorithms in Section Two. In Section One, the chart will guide the user through headcahe symptoms to a selection of possible diagnoses. In Section Two the algorithms will indicate the diagnoses possible with a variety of neurological presenting symptoms. Once a diagnosis has, or number of differential diagnoses have been made, a detailed explanation of the various diagnoses can be found in the largest part of the book, Section Three. This has been written in a style that should be easy to understand by even junior medical students, with technical terms explained in each monograph, but should still be useful to the non-specialist doctor. -
Editorial News
NEWSLETTER 13 | JUNE 2016 MAX IV ©Lunds Universitet EDITORIAL NEWS Are you superstitious? Then read no further… this is the INAUGURATION OF MAX IV IN Lund: “THE BRIGHTEST MO- 13th issue of the Röntgen-Ångström-Cluster Newsletter. Do MENT IN THE YEAR TO OPEN THE BRIGHTEST X-RAY SOURCE you avoid the number 13 for fear of bad things happening IN THE WORld” to you? As a scientist, you are most likely NOT infl uenced by beliefs which by their very nature lack a scientifi c basis. On “We will open the brightest X-ray source in the world on the the contrary, you will show determination to come to the brightest moment in the year”, predicted Christoph Quitmann, essence of phenomena not yet explained in facts and fi gu- Director of MAX IV in Lund, two years ago in an exclusive in- res. Below, you can read about past and present recipients terview for the Röntgen-Ångström-Cluster Newsletter. As it of RÅC funding who demonstrate just that: a keen interest turns out, he was right. The research facility MAX IV in Lund in pursuing goals that no one before them has achieved. celebrated its inauguration on 21st of June, 2016, shortly be- fore Midsummer Day in Sweden. Among the guests to attend However, science and popular customs can be combined, the celebration were the Swedish King and Prime Minister. as we can see in Lund. MAX IV has chosen to open the At present, the team is focused on completing the MAX IV world’s brightest X-ray source on a symbolic day: Swe- Phase I project and on serving fi rst commissioning users later dish Midsummer. -
Top 10 Cool New Features in SAP® Sybase® SQL Anywhere® 16
Top 10 Cool New Features In SAP® Sybase® SQL Anywhere® 16 By: Breck Carter Introduction SAP Sybase SQL Anywhere 16 is the first new release of SAP Sybase SQL Anywhere since version 12 in 2010... that’s a pretty good track record, skipping over one version number per year for three years. It is possible that version numbers 13 and 14 were passed over for the usual reasons of triskaidekaphobia and tetraphobia (fear of the numbers 13 and 4), and it is also possible that number 15 was skipped because it’s been used by SAP Sybase ASE since, well, forever, and SAP Sybase SQL Anywhere 15 would perpetuate the myth that SQL Anywhere and ASE are somehow related. So, we’ve got SAP Sybase SQL Anywhere 16, what’s cool about it? Well, first of all, for the record, it’s got all the same cool stuff found in version 12, nothing big has been jettisoned, not even SQL Remote (so many folks fret about that, having been burned by other vendors forcing Upgrade Death Marches of dubious value). Performance is improved, but that’s not discussed in this article because (a) the performance enhancements are covered in the documentation, (b) it’s too early to tell exactly what the effects are, and (c) without a Woohoo! case study or two to drive home the point I would just be reading the Help to you. Another big new feature in SQL Anywhere 16 is the Role-Based Security Model, a breathtaking revision of GRANT and REVOKE involving seven new and replaced SQL statements, six new system procedures, six new database and server options, and a whole new way of looking at things: “Whereas before you had authorities, permissions, object-level permissions, and groups, you now have roles, system privileges, object-level privileges, and user-extended roles.” The release-defining Role-Based Security Model isn’t fully covered in this article because, frankly, it’s just too big to fit.. -
Psychopathology-Madjirova.Pdf
NADEJDA PETROVA MADJIROVA PSYCHOPATHOLOGY psychophysiological and clinical aspects PLOVDIV 2005 I devote this book to all my patients that shared with me their intimate problems. © Nadejda Petrova Madjirova, 2015 PSYCHOPATHOLOGY: PSYCHOPHYSIOLOGICAL AND CLINICAL ASPECTS Prof. Dr. Nadejda Petrova Madjirova, MD, PhD, DMSs Reviewer: Prof. Rumen Ivandv Stamatov, PhD, DPS Prof. Drozdstoj Stoyanov Stoyanov, PhD, MD Design: Nadejda P. Madjirova, MD, PhD, DMSc. Prepress: Galya Gerasimova Printed by ISBN I. COMMON ASPECTS IN PSYCHOPHYSIOLOGY “A wise man ought to realize that health is his most valuable possession” Hippocrates C O N T E N T S I. Common aspects in psychophysiology. ..................................................1 1. Some aspects on brain structure. ....................................................5 2. Lateralisation of the brain hemispheres. ..........................................7 II. Experimental Psychology. ..................................................................... 11 1. Ivan Petrovich Pavlov. .................................................................... 11 2. John Watson’s experiments with little Albert. .................................15 III. Psychic spheres. ...................................................................................20 1. Perception – disturbances..............................................................21 2. Disturbances of Will .......................................................................40 3. Emotions ........................................................................................49 -
เวชศาสตร์ฟื้นฟูทันสมัยในผู้ป่วยพาร์กินสัน 103 March-April 2010
บทความพเศษิ Chula Med J Vol. 54 No. 2 March - April 2010 เวชศาสตรฟ์ นฟ้ื ทู นสมั ยในผั ปู้ วยพาร่ ก์ นสิ นั อารรี ตนั ์ สพุ ทธุ ธาดาิ * Suputtitada A. Up-to-date rehabilitation in Parkinson’s patients. Chula Med J 2010 Mar - Apr; 54(2): 101 - 10 Parkinson’s disease is a degenerative brain disease. The dopamine producing cells in substantia nigra of basal ganglia are progressively degenerate. This causes patients unable to control their movements. Symptoms usually show up with bradykinesia, or slowness of movement and one or more of three following symptoms: (1) tremor, or trembling in hands, arms, legs, jaw, and face, (2) rigidity, or stiffness of limbs and trunk (3) postural instability. In addition, abnormal autonomic nervous system, pain sensation, swallowing, bowel and bladder, sexual, emotion can present. At present, research and clinical evidences reveal that rehabilitation treatment can help the patients improve walking and movement abilities, have better balance, decrease fall risk, increase activities of daily living, and improve quality of life. Keywords: Parkinson’s disease, Walk, Balance, Rehabilitation. Reprint request: Suputtitada A. Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Received for publication. September 15, 2009. *ภาควิชาเวชศาสตร์ฟื้นฟ ู คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวทยาลิ ยั 102 อารรี ตนั ์ สพุ ทธุ ธาดาิ Chula Med J อารรี ตนั ์ สพุ ทธุ ธาดาิ . เวชศาสตรฟ์ นฟ้ื ทู นสมั ยในผั ปู้ วยพาร่ ก์ นสิ นั . จฬาลงกรณุ เวชสาร์ 2553 ม.ี ค. - เม.ย.; 54(2): 101 - 10 -
Handbook on Clinical Neurology and Neurosurgery
Alekseenko YU.V. HANDBOOK ON CLINICAL NEUROLOGY AND NEUROSURGERY FOR STUDENTS OF MEDICAL FACULTY Vitebsk - 2005 УДК 616.8+616.8-089(042.3/;4) ~ А 47 Алексеенко Ю.В. А47 Пособие по неврологии и нейрохирургии для студентов факуль тета подготовки иностранных граждан: пособие / составитель Ю.В. Алексеенко. - Витебск: ВГМ У, 2005,- 495 с. ISBN 985-466-119-9 Учебное пособие по неврологии и нейрохирургии подготовлено в соответствии с типовой учебной программой по неврологии и нейрохирургии для студентов лечебного факультетов медицинских университетов, утвержденной Министерством здравоохра нения Республики Беларусь в 1998 году В учебном пособии представлены ключевые разделы общей и частной клиниче ской неврологии, а также нейрохирургии, которые имеют большое значение в работе врачей общей медицинской практики и системе неотложной медицинской помощи: за болевания периферической нервной системы, нарушения мозгового кровообращения, инфекционно-воспалительные поражения нервной системы, эпилепсия и судорожные синдромы, демиелинизирующие и дегенеративные поражения нервной системы, опу холи головного мозга и черепно-мозговые повреждения. Учебное пособие предназначено для студентов медицинского университета и врачей-стажеров, проходящих подготовку по неврологии и нейрохирургии. if' \ * /’ L ^ ' i L " / УДК 616.8+616.8-089(042.3/.4) ББК 56.1я7 б.:: удгритний I ISBN 985-466-119-9 2 CONTENTS Abbreviations 4 Motor System and Movement Disorders 5 Motor Deficit 12 Movement (Extrapyramidal) Disorders 25 Ataxia 36 Sensory System and Disorders of Sensation -
An Introduction to the Journal of Behavioral and Experimental Finance
Accepted Manuscript An introduction to the Journal of Behavioral and Experimental Finance Brian M. Lucey PII: S2214-6350(14)00011-2 DOI: http://dx.doi.org/10.1016/j.jbef.2014.02.003 Reference: JBEF 10 To appear in: Journal of Behavioral and Experimental Finance Please cite this article as: Lucey, B.M., An introduction to the Journal of Behavioral and Experimental Finance. Journal of Behavioral and Experimental Finance (2014), http://dx.doi.org/10.1016/j.jbef.2014.02.003 This is a PDF file of an unedited manuscript that has been accepted for publication. Asa service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. An Introduction to the Journal of Behavioral and Experimental Finance This issue is the first of a new Journal, Journal of Behavioral and Experimental Finance. The aim of the journal is to provide a single place for the intersection of two distinct fields; finance (in the broadest sense) and behavioral/experimental approaches. Finance is now mature as a discipline, and behavioral / experimental economics has achieved a solid status. Yet, despite growing usage of the experimental toolkit in finance and the growth of learned associations in the area no journal existed as an outlet dedicated to this endeavor. Similarly behavioral approaches have become common as lenses through which to view financial issues, and while there do exist some journals it is clear that this is a field that is underserved Academic peer reviewed journals are, for all their problems and issues, at the very core of how researchers communicate in the modern academy. -
Medical Management of Parkinson's Disease
3 Differential Diagnosis of Parkinsonism and Tremor Dr D Grosset Consultant Neurologist and Honorary Professor, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow When Do Symptoms Develop? In PD, symptoms develop after the reserve capacity of dopaminergic neurones is exhausted. 18F- fluorodopa PET studies suggest that this probably occurs after at least 50% of dopaminergic neurones have degenerated, lower than previous estimates of 60 to 80%. However, enhanced synthesis of dopamine in surviving neurones (upregulation of striatal dopa decarboxylase activity) and increased dopaminergic stimulation of the striatum may underestimate the true proportion of cell loss. Symptoms may be present for some time (occasionally years) before the diagnosis is made, particularly in younger patients. Abnormalities in pre-synaptic dopamine turnover or dopamine transporter levels are detectable on functional imaging. Patients lose their sense of smell in the pre-clinical phase of PD. Olfactory dysfunction is found in 70- 80% of PD patients and is therefore as common as tremor, but loss of sense of smell occurs with aging and most hyposmic people do not get PD: Olfactory dysfunction also occurs in dementia with Lewy bodies Olfaction remains normal in PSP, corticobasal degeneration and vascular parkinsonism In MSA, spinocerebellar syndromes and essential tremor, any olfactory disturbance is mild Olfactory loss is usually not volunteered by the patient, who may only realise it once asked or with testing Olfactory loss tends not to occur in one of the genetic types of PD (Parkin). A higher rate of PD is reported in patients with essential tremor, and in families with essential tremor, but quantifying the relationship is difficult: Functional imaging studies suggests two separate entities As essential tremor is relatively common, is it inevitable that some patients with essential tremor will later develop PD Rarely, familial essential tremor occurs in conjunction with familial PD A subset of patients present temporally with ET and PD. -
Numbers 1 to 100
Numbers 1 to 100 PDF generated using the open source mwlib toolkit. See http://code.pediapress.com/ for more information. PDF generated at: Tue, 30 Nov 2010 02:36:24 UTC Contents Articles −1 (number) 1 0 (number) 3 1 (number) 12 2 (number) 17 3 (number) 23 4 (number) 32 5 (number) 42 6 (number) 50 7 (number) 58 8 (number) 73 9 (number) 77 10 (number) 82 11 (number) 88 12 (number) 94 13 (number) 102 14 (number) 107 15 (number) 111 16 (number) 114 17 (number) 118 18 (number) 124 19 (number) 127 20 (number) 132 21 (number) 136 22 (number) 140 23 (number) 144 24 (number) 148 25 (number) 152 26 (number) 155 27 (number) 158 28 (number) 162 29 (number) 165 30 (number) 168 31 (number) 172 32 (number) 175 33 (number) 179 34 (number) 182 35 (number) 185 36 (number) 188 37 (number) 191 38 (number) 193 39 (number) 196 40 (number) 199 41 (number) 204 42 (number) 207 43 (number) 214 44 (number) 217 45 (number) 220 46 (number) 222 47 (number) 225 48 (number) 229 49 (number) 232 50 (number) 235 51 (number) 238 52 (number) 241 53 (number) 243 54 (number) 246 55 (number) 248 56 (number) 251 57 (number) 255 58 (number) 258 59 (number) 260 60 (number) 263 61 (number) 267 62 (number) 270 63 (number) 272 64 (number) 274 66 (number) 277 67 (number) 280 68 (number) 282 69 (number) 284 70 (number) 286 71 (number) 289 72 (number) 292 73 (number) 296 74 (number) 298 75 (number) 301 77 (number) 302 78 (number) 305 79 (number) 307 80 (number) 309 81 (number) 311 82 (number) 313 83 (number) 315 84 (number) 318 85 (number) 320 86 (number) 323 87 (number) 326 88 (number) -
Dementia – Etiology and Epidemiology
Dementia – Etiology and Epidemiology A Systematic Review Volume 1 June 2008 The Swedish Council on Technology Assessment in Health Care SBU • Statens beredning för medicinsk utvärdering SBU Evaluates Healthcare Technology SBU (the Swedish Council on Technology Assessment in Health Care) is a government agency that assesses the methods employed by medical professionals and institutions. In addition to analyzing the costs and benefits of various health care measures, the agency weighs Swedish clinical practice against the findings of medical research. The objective of SBU’s activities is to provide everyone who is involved in decisions about the conduct of health care with more complete and accurate information. We welcome you to visit our homepage on the Internet at www.sbu.se. SBU issues three series of reports. The first series, which appears in a yellow binding, presents assessments that have been carried out by the agency’s project groups. A lengthy summary, as well as a synopsis of measures proposed by the SBU Board of Directors and Scientific Advisory Committee, accompanies every assessment. Each report in the second, white-cover series focuses on current research in a parti- cular healthcare area for which assessments may be needed. The Alert Reports, the third series, focus on initial assessments of new healthcare measures. To order this report (No 172E/1) please contact: SBU Mailing Address: Box 5650, SE-114 86 Stockholm, Sweden Street Address: Tyrgatan 7 Tel: +46 8 412 32 00 Fax: +46 8 411 32 60 Internet: www.sbu.se E-mail: [email protected]